Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety

By J. Vahle, Masahiko Sato, G. Long, Jamie K. Young, P. Francis, J. Engelhardt, M. Westmore, Yanfei Ma, J. Nold. Toxicologic pathology (Print), 2002

657 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2018, background): “Studies in rats have indicated an increased incidence of osteosarcoma, with long-term administration of very high doses of teriparatide [255, 256].”
The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis (2003, methodology): “Kurland et al.(12) also found that endogenous PTH fell by 50% from baseline at 6 months in a group of osteoporotic men treated with 400 IU PTH (1-34) daily (approximately equivalent to 25 g), and was 40% lower after 18 months of therapy (p 0.05 vs. placebo).”
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. (2005, methodology): “Osteosarcoma was found at all dose levels, and, in the lower dose ranges, was first detected after approximately 20 months of therapy (87).”